Clinical Trial Highlights

H1 core operating margin evolution Reflected dilutive impact from recent acquisitions 39.6% Core Operating margin (as a % of total sales) -0.7% -7.6% Base business • . 2.1% 0.5% 34.0% H1 2022 Base business Acquisitions Onivyde rights FX H1 2023 Contribution of growth platforms Pre-launch & RoW commercial activities & existing pipeline investment Gradual decline of Somatuline Acquisitions · . Epizyme & Albireo dilutive impact based on commercial & R&D investments Limited synergies to date Onivyde rights • Upfront fee from licence rights with ex- U.S. partner for 1L PDAC Strong underlying level of core operating margin at 34% of total sales IPSEN Innovation for patient care 1L: first line; PDAC: pancreatic ductal adenocarcinoma. 12

View entire presentation